首页 > 最新文献

Clinical Diabetes最新文献

英文 中文
Section 15: Management of Diabetes in Pregnancy. 第 15 节：妊娠期糖尿病管理。
Q2 Medicine
Clinical Diabetes
Pub Date : 2024-01-01 Epub Date: 2024-04-15 DOI: 10.2337/cd24-a015
{"title":"Section 15: Management of Diabetes in Pregnancy.","authors":"","doi":"10.2337/cd24-a015","DOIUrl":"https://doi.org/10.2337/cd24-a015","url":null,"abstract":"","PeriodicalId":39894,"journal":{"name":"Clinical Diabetes","volume":"42 2","pages":"220-221"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11040023/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140866815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Section 9: Pharmacologic Approaches to Glycemic Treatment. 第 9 节：降糖治疗的药物方法。
Q2 Medicine
Clinical Diabetes
Pub Date : 2024-01-01 Epub Date: 2024-04-15 DOI: 10.2337/cd24-a009
{"title":"Section 9: Pharmacologic Approaches to Glycemic Treatment.","authors":"","doi":"10.2337/cd24-a009","DOIUrl":"https://doi.org/10.2337/cd24-a009","url":null,"abstract":"","PeriodicalId":39894,"journal":{"name":"Clinical Diabetes","volume":"42 2","pages":"206-208"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11040009/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140859029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Intra-Articular Corticosteroid Injection on Glycemic Control: A Population-Based Cohort Study. 关节内皮质类固醇注射对血糖控制的影响:一项基于人群的队列研究
Q2 Medicine
Clinical Diabetes
Pub Date : 2024-01-01 Epub Date: 2023-08-25 DOI: 10.2337/cd22-0124
Terin T Sytsma, Laura S Greenlund, Karen M Fischer, Rozalina G McCoy

This retrospective cohort study investigated the longer-term hyperglycemic effects of intra-articular corticosteroid (IACS) administration by evaluating changes in A1C after large joint IACS injection. Among 1,169 patients (mean age 66.1 ± 12.2 years, 52.8% female), 184 (15.7%) experienced a greater-than-expected rise in A1C (actual A1C ≥0.5% above predicted) after IACS. Greater-than-expected rise in A1C was associated solely with baseline A1C (odds ratio [OR] 1.84, 95% CI 1.08-3.13 for baseline A1C of 7.0-8.0% compared with <7.0% and OR 4.79, 95% CI 2.83-8.14 for baseline A1C >8.0% compared with <7.0%). Although most patients do not experience an increase in A1C after IACS, clinicians should counsel patients with suboptimally controlled diabetes about risks of further hyperglycemia after IACS administration.

这项回顾性队列研究通过评估大关节IACS注射后A1C的变化，调查了关节内皮质类固醇（IACS）给药的长期高血糖影响。在1169名患者（平均年龄66.1±12.2岁）中，52.8%为女性），184名（15.7%）在IACS后A1C升高幅度大于预期（实际A1C≥预测值的0.5%）。A1C高于预期的升高仅与基线A1C相关（基线A1C的比值比[OR]1.84（95%CI 1.08-1.13）为7.0-8.0%，而基线A1C为8.0%，而<7.0%为8.0%。尽管大多数患者在IACS后A1C没有增加，但临床医生应就IACS给药后糖尿病控制不佳的患者进一步高血糖的风险向其提供建议。
{"title":"Impact of Intra-Articular Corticosteroid Injection on Glycemic Control: A Population-Based Cohort Study.","authors":"Terin T Sytsma, Laura S Greenlund, Karen M Fischer, Rozalina G McCoy","doi":"10.2337/cd22-0124","DOIUrl":"10.2337/cd22-0124","url":null,"abstract":"<p><p>This retrospective cohort study investigated the longer-term hyperglycemic effects of intra-articular corticosteroid (IACS) administration by evaluating changes in A1C after large joint IACS injection. Among 1,169 patients (mean age 66.1 ± 12.2 years, 52.8% female), 184 (15.7%) experienced a greater-than-expected rise in A1C (actual A1C ≥0.5% above predicted) after IACS. Greater-than-expected rise in A1C was associated solely with baseline A1C (odds ratio [OR] 1.84, 95% CI 1.08-3.13 for baseline A1C of 7.0-8.0% compared with <7.0% and OR 4.79, 95% CI 2.83-8.14 for baseline A1C >8.0% compared with <7.0%). Although most patients do not experience an increase in A1C after IACS, clinicians should counsel patients with suboptimally controlled diabetes about risks of further hyperglycemia after IACS administration.</p>","PeriodicalId":39894,"journal":{"name":"Clinical Diabetes","volume":" ","pages":"96-103"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10788672/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43587755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Section 6: Glycemic Goals and Hypoglycemia. 第 6 节：血糖目标和低血糖症。
Q2 Medicine
Clinical Diabetes
Pub Date : 2024-01-01 Epub Date: 2024-04-15 DOI: 10.2337/cd24-a006
{"title":"Section 6: Glycemic Goals and Hypoglycemia.","authors":"","doi":"10.2337/cd24-a006","DOIUrl":"https://doi.org/10.2337/cd24-a006","url":null,"abstract":"","PeriodicalId":39894,"journal":{"name":"Clinical Diabetes","volume":"42 2","pages":"196-200"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11040020/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140866757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Good to Know: Health Equity Bill of Rights. 健康公平权利法案》。
Q2 Medicine
Clinical Diabetes
Pub Date : 2024-01-01 Epub Date: 2024-01-15 DOI: 10.2337/cd24-pe01
{"title":"Good to Know: Health Equity Bill of Rights.","authors":"","doi":"10.2337/cd24-pe01","DOIUrl":"https://doi.org/10.2337/cd24-pe01","url":null,"abstract":"","PeriodicalId":39894,"journal":{"name":"Clinical Diabetes","volume":"42 1","pages":"175-176"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10788647/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139479498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Guaranteed Diabetes Cure. 保证治愈糖尿病
Q2 Medicine
Clinical Diabetes
Pub Date : 2024-01-01 Epub Date: 2024-07-15 DOI: 10.2337/cd24-0033
Stephen A Brunton
{"title":"A Guaranteed Diabetes Cure.","authors":"Stephen A Brunton","doi":"10.2337/cd24-0033","DOIUrl":"https://doi.org/10.2337/cd24-0033","url":null,"abstract":"","PeriodicalId":39894,"journal":{"name":"Clinical Diabetes","volume":"42 3","pages":"357"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11247030/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141627933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Persistence to Basal Insulin: Association With Health Outcomes in a Population With Type 2 Diabetes 基础胰岛素的持久性：与 2 型糖尿病患者的健康结果有关
Q2 Medicine
Clinical Diabetes
Pub Date : 2023-12-19 DOI: 10.2337/cd23-0016
I. Nsiah, Patrick J. Campbell, Megha A. Parikh, Lisa E. Hines, Matthew Pickering, David P. Nau
This study examined the association between persistence to basal insulin and clinical and economic health outcomes. The question of whether a persistence measure for basal insulin could be leveraged in quality measurement was also explored. Using the IBM-Truven MarketScan Commercial and Medicare Supplemental Databases from 1 January 2011 to 31 December 2015, a total of 14,126 subjects were included in the analyses wherein 9,898 (70.1%) were categorized as persistent with basal insulin therapy. Basal insulin persistence was associated with lower A1C, fewer hospitalizations and emergency department visits, and lower health care expenditures. Quality measures based on prescription drug claims for basal insulin are feasible and should be considered for guiding quality improvement efforts.
本研究探讨了基础胰岛素的持续性与临床和经济健康结果之间的关系。研究还探讨了基础胰岛素的持续性衡量标准是否可用于质量衡量的问题。利用IBM-Truven MarketScan商业数据库和医疗保险补充数据库（2011年1月1日至2015年12月31日），共有14126名受试者被纳入分析，其中9898人（70.1%）被归类为持续接受基础胰岛素治疗。坚持使用基础胰岛素与降低 A1C、减少住院和急诊就诊次数以及降低医疗支出有关。基于基础胰岛素处方药索赔的质量衡量标准是可行的，应考虑用于指导质量改进工作。
{"title":"Persistence to Basal Insulin: Association With Health Outcomes in a Population With Type 2 Diabetes","authors":"I. Nsiah, Patrick J. Campbell, Megha A. Parikh, Lisa E. Hines, Matthew Pickering, David P. Nau","doi":"10.2337/cd23-0016","DOIUrl":"https://doi.org/10.2337/cd23-0016","url":null,"abstract":"This study examined the association between persistence to basal insulin and clinical and economic health outcomes. The question of whether a persistence measure for basal insulin could be leveraged in quality measurement was also explored. Using the IBM-Truven MarketScan Commercial and Medicare Supplemental Databases from 1 January 2011 to 31 December 2015, a total of 14,126 subjects were included in the analyses wherein 9,898 (70.1%) were categorized as persistent with basal insulin therapy. Basal insulin persistence was associated with lower A1C, fewer hospitalizations and emergency department visits, and lower health care expenditures. Quality measures based on prescription drug claims for basal insulin are feasible and should be considered for guiding quality improvement efforts.","PeriodicalId":39894,"journal":{"name":"Clinical Diabetes","volume":" 27","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138962408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Teplizumab: Is It a Milestone for Type 1 Diabetes or a Risk Factor for Other Autoimmune Diseases in the Long-Term? 替普利珠单抗：它是 1 型糖尿病的里程碑，还是其他自身免疫性疾病的长期风险因素？
Q2 Medicine
Clinical Diabetes
Pub Date : 2023-12-15 DOI: 10.2337/cd23-0073
Gulsum Ozen, Dario Iafusco
{"title":"Teplizumab: Is It a Milestone for Type 1 Diabetes or a Risk Factor for Other Autoimmune Diseases in the Long-Term?","authors":"Gulsum Ozen, Dario Iafusco","doi":"10.2337/cd23-0073","DOIUrl":"https://doi.org/10.2337/cd23-0073","url":null,"abstract":"","PeriodicalId":39894,"journal":{"name":"Clinical Diabetes","volume":"70 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138997534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sensor-Derived A1C: A New and Better Term 传感器得出的 A1C：一个更好的新术语
Q2 Medicine
Clinical Diabetes
Pub Date : 2023-12-14 DOI: 10.2337/cd23-0083
Ian R. Blumer
{"title":"Sensor-Derived A1C: A New and Better Term","authors":"Ian R. Blumer","doi":"10.2337/cd23-0083","DOIUrl":"https://doi.org/10.2337/cd23-0083","url":null,"abstract":"","PeriodicalId":39894,"journal":{"name":"Clinical Diabetes","volume":"406 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138974123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-Term Mortality After Charcot Reconstruction 夏科重建术后的长期死亡率
Q2 Medicine
Clinical Diabetes
Pub Date : 2023-12-12 DOI: 10.2337/cd23-0030
Cameron Meyer, Amanda Marshall, Patrick Burns
Charcot neuroarthropathy is a complicated phenomenon with the potential to cause significant deformity, morbidity, and mortality. Costs associated with Charcot-related complications are substantial, with thousands of amputations occurring annually. The purpose of this study was to retrospectively review a single surgeon's experience and record the 10-year mortality rate among patients after Charcot reconstruction at a single institution between 2007 and 2013. Lower-extremity limb salvage is crucial to reduce the burden of Charcot neuroarthropathy. This article provides an example of the potential long-term success of reconstruction surgery for this condition.
夏科神经关节病是一种复杂的疾病，有可能导致严重的畸形、发病率和死亡率。与 Charcot 相关并发症有关的费用非常高昂，每年都会发生数千例截肢。本研究旨在回顾一位外科医生的手术经验，并记录 2007 年至 2013 年间在一家医疗机构接受夏科重建手术的患者的 10 年死亡率。下肢肢体救治对于减轻夏科神经关节病的负担至关重要。本文举例说明了针对这种病症的重建手术可能取得的长期成功。
{"title":"Long-Term Mortality After Charcot Reconstruction","authors":"Cameron Meyer, Amanda Marshall, Patrick Burns","doi":"10.2337/cd23-0030","DOIUrl":"https://doi.org/10.2337/cd23-0030","url":null,"abstract":"Charcot neuroarthropathy is a complicated phenomenon with the potential to cause significant deformity, morbidity, and mortality. Costs associated with Charcot-related complications are substantial, with thousands of amputations occurring annually. The purpose of this study was to retrospectively review a single surgeon's experience and record the 10-year mortality rate among patients after Charcot reconstruction at a single institution between 2007 and 2013. Lower-extremity limb salvage is crucial to reduce the burden of Charcot neuroarthropathy. This article provides an example of the potential long-term success of reconstruction surgery for this condition.","PeriodicalId":39894,"journal":{"name":"Clinical Diabetes","volume":"26 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139008526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
类型
全部 化学•材料 生命科学 医学 物理 工程技术 环境•农林 材料科学 地球科学 法学 管理学 化学 环境科学与生态学 计算机科学 教育学 经济学 农林科学 人文科学 生物学 数学 物理与天体物理 心理学 综合性期刊 其他 工业工程 理学 历史学 农学 文学 信息工程
数据库
全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley
期刊
Clinical Diabetes
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
﹀
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们：info@booksci.cn
Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1